o Acacia Pharma Ltd., of Cambridge, UK, said it started its first clinical trial, a Phase I study of APD 405 for the prevention and treatment of nausea and vomiting after surgery and treatment with chemotherapy drugs. The trial is a single ascending dose study of the safety, tolerability and pharmacokinetics of APD 405, a reformulation of an existing marketed drug, in healthy volunteers. Acacia identified the new use for the drug after noting that the active ingredient in APD 405 hits two proven, complementary anti-emetic pathways.
o Amsterdam Molecular Therapeutics BV, of Amsterdam, the Netherlands, obtained a license from Amgen Inc., of Thousand Oaks Calif., to use its GDNF gene for the development of a gene therapy treatment for Parkinson's disease. AMT said its gene-delivery platform potentially may provide a solution for delivering GDNF to the brain. The GDNF gene contains the information for a protein necessary for the development and survival of nerve cells.
o Apogenix GmbH, of Heidelberg, Germany, said its research programs have received two grants totaling C1.65 million (US$2.38 million) from the German Federal Ministry of Education and Research. Under the terms of the first grant, Apogenix s research collaboration partner at Stuttgart University will receive C500,000 of a grant totaling C1.35 million to study the potential application of stable, apoptosis-inducing ligands of the tumor necrosis factor superfamily for therapeutics against tumors. Another collaboration with the Junior Group Molecular Neurobiology at the German Cancer Research Center will receive C300,000 to study Apogenix' lead candidate APG101 in a new indication, glioblastoma multiforme.
o Basilea Pharmaceutica Ltd., of Basel, Switzerland, said Toctino (alitretinoin), a once-daily …
Комментариев нет:
Отправить комментарий